


EDG-15400, An Investigational Cardiac Sarcomere Modulator, Demonstrated Favorable Pharmacokinetics, Pharmacodynamics, and Tolerability in Healthy Adult Participants

Marilyn Mok, PhD
Associate Director, DMPK
Edgewise Therapeutics



Presentation Background




- The following slides were presented as part of HFSA's 2026 Oral Abstract Rapid Fire session where presenters had 5 minutes for the oral update and 2 minutes of Q&A to share their findings.

First-in-Human Phase 1 Study of EDG-15400, An Investigational Novel Cardiac Sarcomere Modulator, in Heart Failure with Preserved Ejection Fraction



- HFpEF is a syndrome of heart failure in which LVEF is preserved, but ventricular relaxation and filling are impaired
- EDG-15400 is an investigational oral small molecule designed to accelerate ventricular relaxation without affecting overall systolic function
- EDG-15400-101 was a FIH Phase 1 study in healthy adult participants

EDG-15400-101 Study Design



EDG-15400 is not approved by any regulatory agency in any region

EDG-15400 was Rapidly Absorbed and Well-Tolerated with No Food Effect



TEAEs after multiple ascending doses of EDG-15400

Adverse events	Pooled Placebo (N=8)	EDG-15400				
		Pooled Active (N=24)	10mg (N=6)	20mg (N=6)	40mg (N=6)	80mg (N=6)
Subjects with any TEAE, n	2	6	0	0	4	2
Respiratory, thoracic and mediastinal	0	2	0	0	1	1
Nervous system disorders	1	2	0	0	1	1
Musculoskeletal and connective tissue	1	1	0	0	1	0
General disorders and administrative site conditions	1	1	0	0	0	1
Gastrointestinal disorders	1	2	0	0	2	0
Blood and lymphatic system disorders	0	2	0	0	2	0

EDG-15400 is not approved by any regulatory agency in any region

Summary

- EDG-15400 was well-tolerated
 - No clinically meaningful changes or trends in clinical chemistry, hematology, ECGs, or echocardiograms (no significant decrease in LVEF)
- EDG-15400 exhibited favorable once-daily dosing properties
 - Dose-proportional and linear PK
 - No food effect
- EQUINOX-HFpEF Phase 2 study ongoing



Acknowledgements

Edgewise Therapeutics thanks all the study participants, site investigators, and site personnel for their involvement in our clinical studies.

